Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Utkarsh Goel, Danai Dima, James A Davis, Aliya Rashid, William Wesson, Shaun DeJarnette, Fauzia Ullah, Evguenia Ouchveridze, Mariam Markouli, Claire Yun Kyoung Ryu Tiger, Louis Williams, Sandra Mazzoni, Beth M. Faiman, Craig Sauter, Faiz Anwer, Shahzad Raza, Leyla O. Shune, Jack Khouri

Blood (2024) 144 (Supplement 1): 4708.

https://doi.org/10.1182/blood-2024-203984

Published: 2024

Journal Articles

Fostering Collaborative Care in Multiple Myeloma: An Update on the Impact of Holistic Education on Decision-Making with Antibody and CAR-T Platforms

Carmine Deluca, Robert Z. Orlowski, Jennifer M. Ahlstrom, Beth M. Faiman, Irene Ghobrial, Michael Beyer, Marina Wanes, Abigail Brugger

Blood (2024) 144 (Supplement 1): 7961.

https://doi.org/10.1182/blood-2024-211443

Published: 2024

Journal Articles

Improving Specialty Access for Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Plasma Cell Disorders (PCDs): 10 Years of Experience and a Successful Model of Care

Beth M. Faiman, Louis S Williams, Jack Khouri, Faiz Anwer, Shahzad Raza, Christy J. Samaras, Kimberly Hamilton, Cynthia Scott, Saveta Mathur, Omer N. Koc, Willem J. van Heeckeren, Jason Valent, Sandra Mazzoni

Blood (2024) 144 (Supplement 1): 5170.8.

https://doi.org/10.1182/blood-2024-212088

Published: 2024

Journal Articles

Impact of T-Cell Redirecting Therapies on Survival Outcomes in Ultra-High-Risk Multiple Myeloma and Plasma Cell Leukemia

Hassan Elmaleh, Hong Li, Shahzad Raza, Sandra Mazzoni, Christy J. Samaras, Beth M. Faiman, Jack Khouri, Jason Valent, Faiz Anwer, Louis S Williams

Blood (2024) 144 (Supplement 1): 7092.

https://doi.org/10.1182/blood-2024-208780

Published: 2024

Journal Articles

US Physicians' Perspective and Practice Patterns for the Management of Transplant-Eligible-Newly Diagnosed Multiple Myeloma

Yara Shatnawi, Zainab Motiwala, Faiz Anwer, Danai Dima, Louis S Williams, Nausheen Ahmed, Sandra Mazzoni, Jack Khouri, Joslyn Rudoni, Mikhaila Rice, Diana Basali, Christy J. Samaras, Jason Valent, Al-Ola Abdallah, Tara Roy, Beth M. Faiman, Shahzad Raza

Blood (2024) 144 (Supplement 1): 7044.

https://doi.org/10.1182/blood-2024-212202

Published: 2024

Journal Articles

Satisfaction and Experiences with Talquetamab: Results from Qualitative Patient and Physician Research

Beth M. Faiman, Cesar Rodriguez, Smith Giri, Christine Brittle, Jay R. Hydren, Karla Mariana Castro Bórquez, Maria Gambill, Ana M. Sahagun Sanchez Aldana, Jennifer M. Ahlstrom, Hoa H. Le, Saurabh N. Patel, Kathleen S Gray, Xinke Zhang, Rafael Fonseca

Blood (2024) 144 (Supplement 1): 3786.

https://doi.org/10.1182/blood-2024-207403

Published: 2024

Journal Articles

A Timelapse Assessment of Education on Heavily Pretreated Multiple Myeloma: Clinician Perceptions and Patient Experiences

Tariqa Ackbarali, Beth M. Faiman, Attaya Suvannasankha, Melissa Alsina, Monique A. Hartley-Brown, Hans C. Lee

Blood (2024) 144 (Supplement 1): 7964.

https://doi.org/10.1182/blood-2024-212026

Published: 2024

Journal Articles

Current Management of Non-Amyloidosis Monoclonal Gammopathy of Renal Significance: Clinical Features, Treatment Selection, Response, and Renal Outcomes in a Recently Treated Patients

Louis Williams, Danai Dima, Hanny Sawaf, Ali Mehdi, Daniel Cancilla, Hira Shaikh, Faiz Anwer, Sandra Mazzoni, Beth M. Faiman, Jack Khouri, Christy J. Samaras, Jason Valent, Shahzad Raza

Blood (2024) 144 (Supplement 1): 1918.

https://doi.org/10.1182/blood-2024-210799

Published: 2024

Journal Articles

Outcomes of Venetoclax-Based Therapy in Patients with Daratumumab-Refractory t(11;14) Positive Light Chain Amyloidosis

Mark Orland, Danai Dima, Fauzia Ullah, Hussein Awada, Diana Basali, Beth M. Faiman, Cynthia Scott, Sandra Mazzoni, Louis S. Williams, Christy J. Samaras, Jason Valent, Faiz Anwer, Shahzad Raza, Jack Khouri

Blood (2023) 142 (Supplement 1): 2031.

https://doi.org/10.1182/blood-2023-183030

Published: 2023

Journal Articles

Insights into Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: A 12-Year Experience of a Large Academic Center

Danai Dima, Fauzia Ullah, Serhan Unlu, Diana Basali, Mahir Khan, Abdullah Saeed Khan, Xuefei Jia, Majid Jaberi-Douraki, Beth M. Faiman, Sandra Mazzoni, Louis S. Williams, Christy J. Samaras, Jason Valent, Faiz Anwer, Jack Khouri, Shahzad Raza

Blood (2023) 142 (Supplement 1): 3407.

https://doi.org/10.1182/blood-2023-181365

Published: 2023

Journal Articles

Outcomes of Salvage VDT-PACE-like Regimens in Relapsed-Refractory Multiple Myeloma: 10-Year Experience of a Large Academic Institution

Arooj Ahmed, Danai Dima, Kerri Row, Fauzia Ullah, Hussein Awada, Diana Basali, Heena Kurish, Mikhaila Rice, Joslyn Rudoni, Marissa Duco, Beth M. Faiman, Jack Khouri, Sandra Mazzoni, Louis S. Williams, Shahzad Raza, Christy J. Samaras, Jason Valent, Faiz Anwer

Blood (2023) 142 (Supplement 1): 4724.

https://doi.org/10.1182/blood-2023-182972

Published: 2023

Journal Articles

The Significance of a “MGUS” Tumor Board

Sandra Mazzoni, Jack Khouri, Louis S. Williams, Beth M. Faiman, Saveta Mathur, Cynthia Scott

Blood (2023) 142 (Supplement 1): 3719.

https://doi.org/10.1182/blood-2023-185050

Published: 2023

Journal Articles

Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score

Rajshekhar Chakraborty, Lisa Rybicki, Wei Wei, Jason Valent, Beth M. Faiman, Christy J. Samaras, Faiz Anwer, Alok A. Khorana

Blood (2022) 140 (23): 2443–2450.

https://doi.org/10.1182/blood.2022015727

Published: 2022

Includes: Supplemental data

Journal Articles

Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant

Hussein Awada, Adel Hajj Ali, Beth M. Faiman, Allison Winter, Sandra Mazzoni, Christy J. Samaras, Craig S. Sauter, Willem J. van Heeckeren, Robert M. Dean, Brad Pohlman, Brian T. Hill, Jason Valent, Ronald M. Sobecks, Louis S. Williams, Deepa Jagadeesh, Betty K. Hamilton, Matt Kalaycio, Faiz Anwer, Jack Khouri

Blood (2022) 140 (Supplement 1): 10596–10597.

https://doi.org/10.1182/blood-2022-168810

Published: 2022

Journal Articles

Long-Term Outcomes of Delayed Neutrophil Engraftment Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 12924–12925.

https://doi.org/10.1182/blood-2022-170385

Published: 2022

Journal Articles

Long-Term Outcomes of Autologous Hematopoietic Cell Transplant of Multiple Myeloma: A 10 Year Follow up Study

Blood (2022) 140 (Supplement 1): 12920–12921.

https://doi.org/10.1182/blood-2022-168262

Published: 2022

Journal Articles

External Validation of the Saved Score for Venous Thromboembolism Risk Stratification in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs

Danai Dima, Ang Li, Lauren M. Granat, Puneet Dhillon, Carmelo Gurnari, Anirudh Yalamanchali, Saeid Mirzai, Wei Wei, Beth M. Faiman, Louis S. Williams, Sandra Mazzoni, Christy J. Samaras, Faiz Anwer, Jason Valent, Jack Khouri

Blood (2022) 140 (Supplement 1): 11299–11300.

https://doi.org/10.1182/blood-2022-165722

Published: 2022

Journal Articles

The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 10592–10593.

https://doi.org/10.1182/blood-2022-168433

Published: 2022

Journal Articles

Predictors of Hospitalizations and Death from COVID-19 in Patients with Multiple Myeloma

Chakra P Chaulagain, Maroun Bou Zerdan, Jack Khouri, Beth M. Faiman, Faiz Anwer, Chieh-Lin Fu, Jason Valent

Blood (2022) 140 (Supplement 1): 12530–12531.

https://doi.org/10.1182/blood-2022-157865

Published: 2022

Journal Articles

Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma

Lauren M Granat, Hong Li, Faiz Anwer, Michael Sheu, Beth M. Faiman, Jack Khouri, Sandra Mazzoni, Jason Valent, Christy J. Samaras, Rajshekar Chakraborty, Chakra P Chaulagain, Willem J. van Heeckeren, Louis S. Williams

Blood (2022) 140 (Supplement 1): 4290–4291.

https://doi.org/10.1182/blood-2022-168040

Published: 2022

NARROW

An Endothelial Activation and Stress Index (EASIX) Based Predictive Model for Neurotoxicity and Cytokine Release Syndrome (CRS) after B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

Fostering Collaborative Care in Multiple Myeloma: An Update on the Impact of Holistic Education on Decision-Making with Antibody and CAR-T Platforms

Improving Specialty Access for Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Plasma Cell Disorders (PCDs): 10 Years of Experience and a Successful Model of Care

Impact of T-Cell Redirecting Therapies on Survival Outcomes in Ultra-High-Risk Multiple Myeloma and Plasma Cell Leukemia

US Physicians' Perspective and Practice Patterns for the Management of Transplant-Eligible-Newly Diagnosed Multiple Myeloma

Satisfaction and Experiences with Talquetamab: Results from Qualitative Patient and Physician Research

A Timelapse Assessment of Education on Heavily Pretreated Multiple Myeloma: Clinician Perceptions and Patient Experiences

Current Management of Non-Amyloidosis Monoclonal Gammopathy of Renal Significance: Clinical Features, Treatment Selection, Response, and Renal Outcomes in a Recently Treated Patients

Outcomes of Venetoclax-Based Therapy in Patients with Daratumumab-Refractory t(11;14) Positive Light Chain Amyloidosis

Insights into Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: A 12-Year Experience of a Large Academic Center

Outcomes of Salvage VDT-PACE-like Regimens in Relapsed-Refractory Multiple Myeloma: 10-Year Experience of a Large Academic Institution

The Significance of a “MGUS” Tumor Board

Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score

Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant

Long-Term Outcomes of Delayed Neutrophil Engraftment Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Long-Term Outcomes of Autologous Hematopoietic Cell Transplant of Multiple Myeloma: A 10 Year Follow up Study

External Validation of the Saved Score for Venous Thromboembolism Risk Stratification in Patients with Multiple Myeloma Receiving Immunomodulatory Drugs

The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma

Predictors of Hospitalizations and Death from COVID-19 in Patients with Multiple Myeloma

Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only